{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T20:16:41Z","timestamp":1793823401041,"version":"4.6.1"},"reference-count":91,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.disamonth.2024.101848","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T07:18:47Z","timestamp":1735802327000},"page":"101848","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Diabetic Kidney Disease"],"prefix":"10.1016","volume":"71","author":[{"given":"Anna","family":"Gaddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Elrggal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hector","family":"Madariaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edgar","family":"Lerma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gates B","family":"Colbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10397","key":"10.1016\/j.disamonth.2024.101848_bib0001","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","article-title":"Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the global burden of disease study 2021","volume":"402","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.disamonth.2024.101848_bib0002","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.2337\/dc14-1296","article-title":"Diabetic kidney disease: a report from an ADA consensus conference","volume":"37","author":"Tuttle","year":"2014","journal-title":"Diabetes Care."},{"key":"10.1016\/j.disamonth.2024.101848_bib0003","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2147\/CLEP.S99518","article-title":"The danish adult diabetes registry","volume":"8","author":"J\u00f8rgensen","year":"2016","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101848_bib0004","doi-asserted-by":"crossref","first-page":"102","DOI":"10.17925\/EE.2022.18.2.102","article-title":"Non-albuminuric diabetic kidney disease phenotype: beyond albuminuria","volume":"18","author":"D'Marco","year":"2022","journal-title":"touchREV Endocrinol"},{"issue":"10","key":"10.1016\/j.disamonth.2024.101848_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.xkme.2024.100889","article-title":"Kidney biopsy findings among patients with diabetes in the cleveland clinic kidney biopsy epidemiology project","volume":"6","author":"Kwon","year":"2024","journal-title":"Kidney Med"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101848_bib0006","doi-asserted-by":"crossref","first-page":"143","DOI":"10.2337\/dc11-1380","article-title":"Diverging association of reduced glomerular filtration rate and albuminuria with coronary and noncoronary events in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study","volume":"35","author":"Solini","year":"2012","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101848_bib0007","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1681\/ASN.2010010010","article-title":"Pathologic classification of diabetic nephropathy","volume":"21","author":"Tervaert","year":"2010","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.1016\/j.disamonth.2024.101848_bib0008","doi-asserted-by":"crossref","first-page":"3620","DOI":"10.2337\/dc12-2572","article-title":"Renal structure in normoalbuminuric and albuminuric patients with type 2 diabetes and impaired renal function","volume":"36","author":"Ekinci","year":"2013","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.disamonth.2024.101848_bib0009","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1507\/endocrj.EJ21-0039","article-title":"Serum stromal cell-derived factor-1 levels are associated with diabetic kidney disease in type 2 diabetic patients","volume":"68","author":"Lu","year":"2021","journal-title":"Endocr J"},{"key":"10.1016\/j.disamonth.2024.101848_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2024.119762","article-title":"Urinary biomarkers in diabetic nephropathy","volume":"561","author":"Soltani-Fard","year":"2024","journal-title":"Clin Chim Acta"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101848_bib0011","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1681\/ASN.2016020231","article-title":"The genetic landscape of renal complications in type 1 diabetes","volume":"28","author":"Sandholm","year":"2017","journal-title":"J Am Soc Nephrol"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101848_bib0012","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00125-014-3459-6","article-title":"SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes","volume":"58","author":"Germain","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.disamonth.2024.101848_bib0013","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/979354","article-title":"Targeted proteomics of isolated glomeruli from the kidneys of diabetic rats: sorbin and SH3 domain containing 2 is a novel protein associated with diabetic nephropathy","volume":"2011","author":"Nakatani","year":"2011","journal-title":"Exp Diabetes Res"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101848_bib0014","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/s12882-020-01901-x","article-title":"Prognostic imaging biomarkers for diabetic kidney disease (iBEAt): study protocol","volume":"21","author":"Gooding","year":"2020","journal-title":"BMC Nephrol"},{"issue":"Supplement_1","key":"10.1016\/j.disamonth.2024.101848_bib0015","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfad063c_5662","article-title":"Loreto gesualdo, #5662 preliminary results from Ibeat ancillary-study: a novel classification of renal damage in diabetes","volume":"38","author":"Pontrelli","year":"2023","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.disamonth.2024.101848_bib0016","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/ki.1981.33","article-title":"Glomerular hemodynamics in experimental diabetes mellitus","volume":"19","author":"Hostetter","year":"1981","journal-title":"Kidney Int"},{"key":"10.1016\/j.disamonth.2024.101848_bib0017","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/MNH.0000000000000756","article-title":"Novel approaches to hypoglycemia and burnt-out diabetes in chronic kidney disease","volume":"31","author":"Rhee","year":"2022","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"10.1016\/j.disamonth.2024.101848_bib0018","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/joim.13424","article-title":"Can we cure diabetic kidney disease? Present and future perspectives from a nephrologist's point of view","volume":"291","author":"Guedes","year":"2022","journal-title":"J Intern Med"},{"key":"10.1016\/j.disamonth.2024.101848_bib0019","doi-asserted-by":"crossref","first-page":"F103","DOI":"10.1152\/ajprenal.00155.2001","article-title":"Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes","volume":"282","author":"Tuttle","year":"2002","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1016\/j.disamonth.2024.101848_bib0020","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1172\/JCI72271","article-title":"Molecular mechanisms of diabetic kidney disease","volume":"124","author":"Reidy","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.disamonth.2024.101848_bib0021","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/ki.2014.271","article-title":"Nlrp3-inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy","volume":"87","author":"Shahzad","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.disamonth.2024.101848_bib0022","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/ki.2014.322","article-title":"Revisiting inflammation in diabetic nephropathy: the role of the Nlrp3 inflammasome in glomerular resident cells","volume":"87","author":"Sakai","year":"2015","journal-title":"Kidney Int"},{"key":"10.1016\/j.disamonth.2024.101848_bib0023","doi-asserted-by":"crossref","first-page":"F716","DOI":"10.1152\/ajprenal.00314.2016","article-title":"Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets","volume":"312","author":"Pichler","year":"2017","journal-title":"Am J Physiol Renal Physiol"},{"issue":"12","key":"10.1016\/j.disamonth.2024.101848_bib0024","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.34067\/KID.0002772021","article-title":"SGLT2 Inhibitors: physiology and pharmacology","volume":"2","author":"Wright","year":"2021","journal-title":"Kidney360"},{"issue":"9","key":"10.1016\/j.disamonth.2024.101848_bib0025","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1007\/s00424-014-1619-7","article-title":"Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart","volume":"467","author":"Vrhovac","year":"2015","journal-title":"Pflugers Arch"},{"issue":"12","key":"10.1016\/j.disamonth.2024.101848_bib0026","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/17425255.2018.1551877","article-title":"The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments","volume":"14","author":"Garcia-Ropero","year":"2018","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.disamonth.2024.101848_bib0027","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.disamonth.2024.101848_bib0028","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1055\/s-0034-1395609","article-title":"Empagliflozin, an inhibitor of sodium-glucose cotransporter 2 exerts anti-inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-receptor axis","volume":"47","author":"Ojima","year":"2015","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.disamonth.2024.101848_bib0029","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/s41581-020-00367-2","article-title":"Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence","volume":"17","author":"Alicic","year":"2021","journal-title":"Nat Rev Nephrol"},{"key":"10.1016\/j.disamonth.2024.101848_bib0030","doi-asserted-by":"crossref","first-page":"967","DOI":"10.3389\/fphar.2020.00967","article-title":"GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms","volume":"11","author":"Kawanami","year":"2020","journal-title":"Front Pharmacol"},{"issue":"Suppl 2","key":"10.1016\/j.disamonth.2024.101848_bib0031","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2337\/diab.32.2.S64","article-title":"The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy","volume":"32","author":"Mogensen","year":"1983","journal-title":"Diabetes"},{"issue":"Suppl 6","key":"10.1016\/j.disamonth.2024.101848_bib0032","first-page":"S228","article-title":"Review on pathophysiology and treatment of diabetic kidney disease","volume":"93","author":"Satirapoj","year":"2010","journal-title":"J Med Assoc Thai"},{"issue":"5S","key":"10.1016\/j.disamonth.2024.101848_bib0033","first-page":"S1","article-title":"KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease","volume":"102","year":"2022","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101848_bib0034","article-title":"Glucose targets for preventing diabetic kidney disease and its progression","volume":"6","author":"Ruospo","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"15","key":"10.1016\/j.disamonth.2024.101848_bib0035","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101848_bib0036","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/jhh.2013.55","article-title":"Hypertension and kidneys: unraveling complex molecular mechanisms underlying hypertensive renal damage","volume":"28","author":"Mennuni","year":"2014","journal-title":"J Hum Hypertens"},{"issue":"3S","key":"10.1016\/j.disamonth.2024.101848_bib0037","first-page":"S1","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","year":"2021","journal-title":"Kidney Int"},{"issue":"22","key":"10.1016\/j.disamonth.2024.101848_bib0038","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1056\/NEJMoa1511939","article-title":"A randomized trial of intensive versus standard blood-pressure control","volume":"373","author":"Wright","year":"2015","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.disamonth.2024.101848_bib0039","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1056\/NEJMoa1001286","article-title":"Effects of intensive blood-pressure control in type 2 diabetes mellitus","volume":"362","author":"Cushman","year":"2010","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.disamonth.2024.101848_bib0040","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1001\/jamainternmed.2017.4377","article-title":"Association between more intensive vs less intensive blood pressure lowering and risk of mortality in chronic kidney disease stages 3 to 5: a systematic review and meta-analysis","volume":"177","author":"Malhotra","year":"2017","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.disamonth.2024.101848_bib0041","doi-asserted-by":"crossref","unstructured":"Brunstr\u00f6m M., Carlberg B. Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med. 2018 Jan 1;178(1):28\u201336. doi: 10.1001\/jamainternmed.2017.6015.","DOI":"10.1001\/jamainternmed.2017.6015"},{"key":"10.1016\/j.disamonth.2024.101848_bib0042","first-page":"29","article-title":"Inhibition of RAS in diabetic nephropathy","volume":"8","author":"Yacoub","year":"2015","journal-title":"Int J Nephrol Renovasc Dis"},{"issue":"20","key":"10.1016\/j.disamonth.2024.101848_bib0043","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. the collaborative study group","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.disamonth.2024.101848_bib0044","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1056\/NEJMoa011489","article-title":"The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes","volume":"345","author":"Parving","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101848_bib0045","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1177\/147323000503300610","volume":"33","author":"Makino","year":"2005","journal-title":"J Int Med Res"},{"issue":"12","key":"10.1016\/j.disamonth.2024.101848_bib0046","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.disamonth.2024.101848_bib0047","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101848_bib0048","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3317\/jraas.2000.002","article-title":"The HOPE study (heart outcomes prevention evaluation)","volume":"1","author":"Sleight","year":"2000","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"issue":"22","key":"10.1016\/j.disamonth.2024.101848_bib0049","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1056\/NEJMoa2210639","article-title":"Renin-angiotensin system inhibition in advanced chronic kidney disease","volume":"387","author":"Bhandari","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101848_bib0050","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/j.ajkd.2022.01.002","article-title":"Hyperkalemia-Related Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in CKD: A Population-Based Cohort Study","volume":"80","author":"Leon","year":"2022","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"10.1016\/j.disamonth.2024.101848_bib0051","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","article-title":"Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients With CKD: a bayesian network meta-analysis of randomized clinical trials","volume":"67","author":"Xie","year":"2016","journal-title":"Am J Kidney Dis"},{"issue":"20","key":"10.1016\/j.disamonth.2024.101848_bib0052","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101848_bib0053","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.mayocpiqo.2022.09.002","article-title":"Evolution of mineralocorticoid receptor antagonists in the treatment of chronic kidney disease associated with type 2 diabetes mellitus","volume":"6","author":"Wish","year":"2022","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"10","key":"10.1016\/j.disamonth.2024.101848_bib0054","article-title":"Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease","volume":"10","author":"Chung","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"24","key":"10.1016\/j.disamonth.2024.101848_bib0055","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.disamonth.2024.101848_bib0056","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of Finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101848_bib0057","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"issue":"12","key":"10.1016\/j.disamonth.2024.101848_bib0058","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101848_bib0059","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","article-title":"Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study","volume":"25","author":"Wada","year":"2021","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101848_bib0060","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"10.1016\/j.disamonth.2024.101848_bib0061","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1002\/ejhf.3294","article-title":"Balcinrenone plus dapagliflozin in patients with heart failure and chronic kidney disease: results from the phase 2b MIRACLE trial","volume":"26","author":"Lam","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"10424","key":"10.1016\/j.disamonth.2024.101848_bib0062","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0140-6736(23)02408-X","article-title":"Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial","volume":"403","author":"Tuttle","year":"2024","journal-title":"Lancet"},{"issue":"10424","key":"10.1016\/j.disamonth.2024.101848_bib0063","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0140-6736(23)02542-4","article-title":"Blocking aldosterone or its receptor-what is the difference?","volume":"403","author":"Agarwal","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101848_bib0064","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1001\/jama.2015.7446","article-title":"Effect of patiromer on serum potassium level in patients with hyperkalemia and diabetic kidney disease: the AMETHYST-DN randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101848_bib0065","doi-asserted-by":"crossref","first-page":"798","DOI":"10.2215\/CJN.12651018","article-title":"Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study","volume":"14","author":"Spinowitz","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"issue":"24","key":"10.1016\/j.disamonth.2024.101848_bib0066","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and Renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.disamonth.2024.101848_bib0067","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.disamonth.2024.101848_bib0068","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1093\/ndt\/gfz033","article-title":"Sodium glucose co-transporter 2 inhibition: a new avenue to protect the kidney","volume":"34","author":"Heerspink","year":"2019","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101848_bib0069","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/s41440-022-01085-x","article-title":"Canagliflozin independently reduced plasma volume from conventional diuretics in patients with type 2 diabetes and chronic heart failure: a subanalysis of the CANDLE trial","volume":"46","author":"Shiina","year":"2023","journal-title":"Hypertens Res"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101848_bib0070","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s12933-022-01492-x","article-title":"Mechanisms underlying the blood pressure lowering effects of dapagliflozin, exenatide, and their combination in people with type 2 diabetes: a secondary analysis of a randomized trial","volume":"21","author":"van Ruiten","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"9","key":"10.1016\/j.disamonth.2024.101848_bib0071","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1111\/dom.14451","article-title":"Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"23","author":"Tsapas","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.disamonth.2024.101848_bib0072","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1097\/HJH.0000000000003280","article-title":"The impact of sodium-glucose cotransporter inhibitors on blood pressure: a meta-analysis and metaregression of 111 randomized-controlled trials","volume":"40","author":"Teo","year":"2022","journal-title":"J Hypertens"},{"key":"10.1016\/j.disamonth.2024.101848_bib0073","doi-asserted-by":"crossref","DOI":"10.1177\/20420188221142450","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on patients with essential hypertension and pre-hypertension: a meta-analysis","volume":"13","author":"Ren","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"18","key":"10.1016\/j.disamonth.2024.101848_bib0074","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1161\/CIRCULATIONAHA.118.037076","article-title":"Twenty-four-hour blood pressure-lowering effect of a sodium-glucose cotransporter 2 inhibitor in patients with diabetes and uncontrolled nocturnal hypertension: results from the randomized, placebo-controlled SACRA study","volume":"139","author":"Kario","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101848_bib0075","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2204233","article-title":"Empagliflozin in patients with chronic kidney disease","volume":"388","author":"Herrington WG","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.disamonth.2024.101848_bib0076","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1111\/dom.13361","article-title":"Semaglutide for type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"20","author":"Andreadis","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"10.1016\/j.disamonth.2024.101848_bib0077","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1053\/j.ajkd.2012.11.043","article-title":"Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial","volume":"61","author":"Arjona Ferreira","year":"2013","journal-title":"Am J Kidney Dis"},{"issue":"10193","key":"10.1016\/j.disamonth.2024.101848_bib0078","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101848_bib0079","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of Semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"issue":"4S","key":"10.1016\/j.disamonth.2024.101848_bib0080","first-page":"S117","article-title":"KDIGO 2024 Clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"issue":"5","key":"10.1016\/j.disamonth.2024.101848_bib0081","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4239\/wjd.v4.i5.190","article-title":"Effects of glucagon-like peptide-1 receptor agonists on renal function","volume":"4","author":"Filippatos","year":"2013","journal-title":"World J Diabetes"},{"issue":"8","key":"10.1016\/j.disamonth.2024.101848_bib0082","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1097\/01.ASN.0000023430.92674.E5","article-title":"Renal tubular acidosis: the clinical entity","volume":"13","author":"Rodr\u00edguez Soriano","year":"2002","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1016\/j.disamonth.2024.101848_bib0083","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/ki.1993.140","article-title":"Pathophysiology of low renin syndromes: sites of renal renin secretory impairment and prorenin overexpression","volume":"43","author":"Lush","year":"1993","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.disamonth.2024.101848_bib0084","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1093\/ndt\/gfab237","article-title":"Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia","volume":"37","author":"Heerspink","year":"2022","journal-title":"Nephrol Dial Transplant"},{"issue":"5","key":"10.1016\/j.disamonth.2024.101848_bib0085","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1093\/ckj\/sfac274","article-title":"Tirzepatide and prevention of chronic kidney disease","volume":"16","author":"Bosch","year":"2022","journal-title":"Clin Kidney J"},{"key":"10.1016\/j.disamonth.2024.101848_bib0086","doi-asserted-by":"crossref","DOI":"10.1681\/ASN.0000000000000444","article-title":"Selonsertib in patients with diabetic kidney disease: a phase 2b randomized active run-in clinical trial","author":"Heerspink","year":"2024","journal-title":"J Am Soc Nephrol"},{"issue":"8","key":"10.1016\/j.disamonth.2024.101848_bib0087","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-053019","article-title":"Pentoxifylline in diabetic kidney disease (VA PTXRx): protocol for a pragmatic randomised controlled trial","volume":"11","author":"Leehey","year":"2021","journal-title":"BMJ Open"},{"key":"10.1016\/j.disamonth.2024.101848_bib0088","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ejphar.2017.06.031","article-title":"Interleukin-33 signaling contributes to renal fibrosis following ischemia reperfusion","volume":"812","author":"Liang","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.disamonth.2024.101848_bib0089","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1016\/j.ekir.2024.03.009","article-title":"Inhibition of Interleukin-33 to reduce glomerular endothelial inflammation in diabetic kidney disease","volume":"9","author":"Hofherr","year":"2024","journal-title":"Kidney Int Rep"},{"issue":"2","key":"10.1016\/j.disamonth.2024.101848_bib0090","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.ekir.2020.11.039","article-title":"Adherence to the kidney disease: improving global outcomes CKD guideline in nephrology practice across countries","volume":"6","author":"Stengel","year":"2021","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.disamonth.2024.101848_bib0091","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1053\/j.ajkd.2022.11.017","article-title":"Predictors, disparities, and facility-level variation: SGLT2 inhibitor prescription among US veterans With CKD","volume":"82","author":"Gregg","year":"2023","journal-title":"Am J Kidney Dis"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502924001743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502924001743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,8]],"date-time":"2025-04-08T08:00:23Z","timestamp":1744099223000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502924001743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":91,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S0011502924001743"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2024.101848","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diabetic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2024.101848","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101848"}}